Degron Therapeutics is discovering and developing a new class of targeted protein degradation therapeutics small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class scientific leaders and industry veterans, bringing its in-depth knowledge in the MGD space to the identification and validation of new MGD targets, particularly those disease drivers but undruggable or insufficiently drugged by other modalities, and to the discovery of novel selective MGD compounds to address unmet medical needs in all therapeutic areas.

In the past, MGDs have been discovered serendipitously. The rational design of MGDs has been extremely challenging due to the complexity of ternary structure formed by E3 ligase-MGD-target Until now.

Differentiated GlueXplorerTM MGD discovery platform enabled by:
- Proprietary and structurally differentiated glue library with 10,000 compounds
- Multiple complementary screening and validation platforms
- Large data sets for AI/Machine Learning

To date, Degron has developed a robust and differentiated pipeline of First-in-Class MGDs for important disease targets.